\
&
Contact us
\
&
Contact us
Published on | 7 months ago
Programmes Health Joint Research CenterThe Joint Research Centre (JRC) of the European Commission has launched a new call in the framework of JRC Open Access to its Research Infrastructures. This is the first call launched by the EU Reference Laboratory for alternatives to animal testing.
The Call offers access to the JRC in vitro High Throughput Testing (HTT) laboratory. This opportunity is available to users who wish to automate their in vitro methods to assess their transferability, reliability, and overall performance. By generating large datasets from bespoke compound libraries, this initiative supports the evaluation of a method’s relevance for specific applications and advances the implementation of non-animal approaches to toxicological testing for the regulatory safety assessment of chemicals.
The call deadline is 31 March 2025.
More information about the call and how to apply on the dedicated webpage.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
